Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.

Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.

OBJECTIVE: To evaluate clinical features among patients with neuromyelitis optica spectrum disorders (NMOSD) who have myelin oligodendrocyte glycoprotein (MOG) antibodies, aquaporin-4 (AQP4) antibodies, or seronegativity for both antibodies. METHODS: Sera from patients diagnosed with NMOSD in 1 of 3...

Full description

Bibliographic Details
Main Authors:	Sato, D, Callegaro, D, Lana-Peixoto, M, Waters, P, de Haidar Jorge, F, Takahashi, T, Nakashima, I, Apostolos-Pereira, S, Talim, N, Simm, R, Lino, A, Misu, T, Leite, M, Aoki, M, Fujihara, K
Format:	Journal article
Language:	English
Published:	American Academy of Neurology 2014

Similar Items

Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.
by: Kezuka, T, et al.
Published: (2014)

RELAPSING AQP4 ANTIBODY NEGATIVE NMO WITH MOG ANTIBODIES
by: Elsone, L, et al.
Published: (2014)

Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders.
by: Sato, D, et al.
Published: (2013)

Prevalence and clinical characteristics of neuromyelitis optica spectrum disorders patients with myelin oligodendrocyte glycoprotein antibodies
by: Sato, D, et al.
Published: (2013)

Seronegative NMO: a sensitive AQP4 antibody test clarifies clinical features and next challenges.
by: Fujihara, K, et al.
Published: (2013)

Anti-MOG Antibodies in Japanese Patients with Neuromyelitis Optica Spectrum Disorders
by: Sato, D, et al.
Published: (2014)

Factors associated with fatigue in CNS inflammatory diseases with AQP4 and MOG antibodies
by: Yeo, T, et al.
Published: (2020)

Distinguishing the brain MRI features of MS, AQP4-and MOG-antibody disease.
by: Jurynczyk, M, et al.
Published: (2016)

Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease.
by: Jurynczyk, M, et al.
Published: (2017)

Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease
by: Jurynczyk, M, et al.
Published: (2017)

THE ASSOCIATION OF TWO RARE NEUROLOGICAL DISEASES: A MULTICENTRE STUDY OF 16 PATIENTS WITH ACHR ANTIBODY MYASTHENIA GRAVIS AND AQP4 ANTIBODY NEUROMYELITIS OPTICA SPECTRUM DISORDER
by: Leite, M, et al.
Published: (2012)

Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies.
by: Kaneko, K, et al.
Published: (2016)

MOG-IGG IN NMO AND NMO-LIKE DISORDERS
by: Luppe, S, et al.
Published: (2014)

Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease
by: Juryńczyk, M, et al.
Published: (2016)

Area postrema syndrome: Frequency, criteria, and severity in AQP4-IgG–positive NMOSD
by: Shosha, E, et al.
Published: (2018)

Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes
by: Juryńczyk, M, et al.
Published: (2015)

International multicenter examination of MOG antibody assays
by: Reindl, M, et al.
Published: (2020)

Time to separate MOG-Ab-associated disease from AQP4-Ab-positive neuromyelitis optica spectrum disorder
by: Hacohen, Y, et al.
Published: (2018)

The influence of smoking on the pattern of disability and relapse risk in AQP4-positive Neuromyelitis Optica Spectrum Disorder, MOG-Ab Disease and Multiple Sclerosis
by: Messina, S, et al.
Published: (2021)

MOG encephalomyelitis: international recommendations on diagnosis and antibody testing
by: Jarius, S, et al.
Published: (2018)

MOG cell-based assay detects non-MS patients with inflammatory neurologic disease
by: Waters, P, et al.
Published: (2015)

NMO-IgG/Aqp4-Ab belongs to the IgG1 subclass and activates complement in vitro
by: Jarius, S, et al.
Published: (2007)

No strong HLA association with MOG antibody disease in the UK population
by: Grant-Peters, M, et al.
Published: (2021)

Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan
by: Kitley, J, et al.
Published: (2012)

Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan.
by: Kitley, J, et al.
Published: (2012)

MOG-IgG1 antibodies in children
by: Waters, P, et al.
Published: (2018)

An international multicentre validation experiment for MOG antibodies
by: Reindl, M, et al.
Published: (2018)

Classifying the antibody-negative NMO syndromes: Clinical, imaging, and metabolomic modeling
by: Yeo, T, et al.
Published: (2019)

Disease course and disability outcomes in MOG-antibody disease in the UK
by: Jurynczyk, M, et al.
Published: (2017)

The Importance of Aquaporin-4 Antibody Assays in Patients beyond the Diagnostic Criteria for Neuromyelitis Optica Spectrum Disorders
by: Sato, D, et al.
Published: (2013)

Recurrent optic neuritis associated with MOG antibody seropositivity
by: Chang, T, et al.
Published: (2017)

Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS
by: Waters, P, et al.
Published: (2015)

Clinical presentation and prognosis in MOG-antibody disease: a UK study
by: Jurynczyk, M, et al.
Published: (2017)

Frequency of Aqp4-Ab in patients with neuromyelitis optica (Devic's syndrome) is higher than predicted by NMO-IgG testing
by: Jarius, S, et al.
Published: (2007)

A 41-year-old woman with acute weakness and encephalopathy associated with MOG antibodies.
by: Morris, K, et al.
Published: (2015)

Peripheral nervous system involvement in MOG antibody-associated demyelination
by: Ramanathan, S, et al.
Published: (2019)

Predictive Value of Anti-Ro Antibody Positivity for Anti-AQP4 Autoantibody Test Results in Patients with Demyelinating Disease of Central Nervous System
by: Kim, J, et al.
Published: (2012)

Glycine receptor antibody — a marker for NMO/ NON-MS demyelination?
by: Hamid, S, et al.
Published: (2015)

Sex ratio and age of onset in AQP4 antibody-associated NMOSD: a review and meta-analysis
by: Arnett, S, et al.
Published: (2024)

Differential diagnosis and utility of AQP4-antibody assays in an insidious case of longitudinally extensive transverse myelitis
by: Rosellini, I, et al.
Published: (2009)